Relatlimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%. Update December 2022

Rothschedl, E. and Wolf, S. (2022): Relatlimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%. Update December 2022. Oncology Fact Sheet Nr. 105.

[thumbnail of Oncology Fact Sheet Nr.105_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
600kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WR Dermatology
Language:	English
Series Name:	Oncology Fact Sheet Nr. 105
Deposited on:	25 Aug 2022 14:24
Last Modified:	27 Dec 2022 12:36

Repository Staff Only: item control page